Published in

SAGE Publications, Clinical Trials, 3(5), p. 225-239, 2008

DOI: 10.1177/1740774508091600

Links

Tools

Export citation

Search in Google Scholar

Imputation methods for missing outcome data in meta-analysis of clinical trials

Journal article published in 2008 by Julian Pt T. Higgins, Ian R. White, Angela M. Wood
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Background: Missing outcome data from randomized trials lead to greater uncertainty and possible bias in estimating the effect of an experimental treatment. An intention-to-treat analysis should take account of all randomized participants even if they have missing observations. Purpose: To review and develop imputation methods for missing outcome data in meta-analysis of clinical trials with binary outcomes. Methods: We review some common strategies, such as simple imputation of positive or negative outcomes, and develop a general approach involving `informative missingness odds ratios' (IMORs). We describe several choices for weighting studies in the meta-analysis, and illustrate methods using a meta-analysis of trials of haloperidol for schizophrenia. Results: IMORs describe the relationship between the unknown risk among missing participants and the known risk among observed participants. They are allowed to differ between treatment groups and across trials. Application of IMORs and other methods to the haloperidol trials reveals the overall conclusion to be robust to different assumptions about the missing data. Limitations: The methods are based on summary data from each trial (number of observed positive outcomes, number of observed negative outcomes and number of missing outcomes) for each intervention group. This limits the options for analysis, and greater flexibility would be available with individual participant data. Conclusions: We propose that available reasons for missingness be used to determine appropriate IMORs. We also recommend a strategy for undertaking sensitivity analyses, in which the IMORs are varied over plausible ranges. Clinical Trials 2008; 5: 225—239. http://ctj.sagepub.com